Leukemia trial pulled before it started: safer transplant prep remains untested

NCT ID NCT02577094

Terminated Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial was designed to test a milder conditioning regimen using a radioactive antibody (90Y-Epratuzumab) followed by chemotherapy and a stem cell transplant for adults with CD22-positive B-cell acute lymphoblastic leukemia. The goal was to find the safest dose that still controls the disease. However, the study was withdrawn before any patients were enrolled, so no data were collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 90Y-Epratuzumab (a radioactive antibody targeting CD22) combined with busulfan, fludarabine, and thymoglobulins
What this could lead to: If it had proceeded, this trial could have pointed toward a safer way to prepare patients for stem cell transplants, potentially reducing side effects while controlling leukemia.
What could go wrong: The trial was withdrawn before enrolling any participants, so no results are available. The approach involves significant risks, including toxicity from radiation and chemotherapy, and it was only in early-phase testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia precursor B-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOCYTE B CD22 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

More trials for these conditions

Other studies related to the condition(s) this trial covers.